Document is current
Any future updates will be listed below
-
Authors
Lin, Jonathan B.
Lin, Joseph B.
Chen, Howard C.
Chen, Teresa
Apte, Rajendra S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM07200, T32 GM07200)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR002345, TL1 TR002344)
Research to Prevent Blindness
Glenn Foundation for Medical Research
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01 EY019287, P30 EY02687)
Reeves Foundation Kuzma Family Gift Jeffrey Fort Innovation Fund Thome Foundation
- License Information
-
More Information
Article History
Received: 21 February 2018
Accepted: 29 November 2018
First Online: 7 March 2019
Competing Interests
: R.S.A. is a co-founder of Metro International, which is developing NMN-based therapeutics. Jonathan B. Lin, Joseph B. Lin, H.C.C., and T.C. declare no potential conflicts of interest.
